The following table sets forth the computation of the Company's basic and diluted net loss per share:


	Three Months Ended March 31,
	2026			2025
Numerator:
Net loss	$	(56,737	)	$	(39,282	)
Denominator:
Shares used to compute net loss per share, basic and diluted
Weighted average shares of common stock outstanding		86,104,331			57,301,916
Weighted average shares of pre-funded warrants to purchase common stock		23,707,130			9,039,389
Weighted average shares of common stock outstanding used to compute basic and diluted net loss per share		109,811,461			66,341,305
Net loss per share, basic and diluted	$	(0.52	)	$	(0.59	)

Included within weighted average shares of common stock outstanding for the three months ended March 31, 2026 and 2025 are 44,408,300 and 16,600,818 shares of common stock issuable upon the exercise of the pre-funded warrants, respectively. The pre‑funded warrants are exercisable at any time for nominal consideration, and as such, the shares are considered outstanding for the purpose of calculating basic and diluted net loss per share.

The outstanding securities presented below were excluded from the calculation of net loss per share because the inclusion of such securities would have been anti-dilutive due to the Company’s net loss during the periods presented.


	Three Months Ended March 31,
	2026		2025
Options to purchase common stock		6,129,390		2,850,441
Nonvested restricted stock units		5,314,517		3,174,668
Nonvested performance stock units		1,555,642		2,165,325
Shares subject to employee stock purchase plan		272,450		234,154
Warrants		2,000		2,563
Total		13,273,999		8,427,151